Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04092634 · ClinicalTrials.gov registry record · Phase 4
Dual Mobility in "High Risk" Patients
A Phase 4 study of Dislocation, Hip, sponsored by Rush University Medical Center.
- Active
- Registry status
- Phase 4
- Development phase
- 412
- Enrollment target
- 4
- Study locations
NCT04092634: Active Phase 4 study of Dislocation, Hip, sponsored by Rush University Medical Center.
NCT04092634 is a Phase 4 study of Dislocation, Hip that is active but no longer recruiting, run by Rush University Medical Center. The registered enrollment target is 412 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (20% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04092634, a Phase 4 study of Dislocation, Hip, is active but no longer recruiting, sponsored by Rush University Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 412 participants
- Enrollment target
- 4
- Study locations
Study Summary
The aim of this study is to compare clinical outcomes of patients considered to be high risk for prosthetic dislocation undergoing primary total hip arthroplasty (THA) with the use of a dual mobility bearing versus a conventional, single bearing design.
Primary Outcome
The rate of prosthetic dislocation between the two cohorts
Conditions Studied
Interventions
- DEVICE Dual mobility implant
- DEVICE Traditional, Single-bearing hip implant
Study Locations (4)
California
- Keck School of Medicine of USC - Los Angeles
Illinois
- Rush University Medical Center - Chicago
New York
- New York University Medical Center - New York
Pennsylvania
- Rothman Orthopaedic Institute - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 412 participants |
| Start Date | 2017-11-01 |
| Est. Completion | 2035-02-01 |
| Phase | Phase 4 |
What the registry record for NCT04092634 still lists
NCT04092634 is an interventional study that assigns participants to a tested intervention. The registered 412 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (20% lower).
The record links to 1 condition, with Dislocation, Hip appearing as the primary indexed condition, and to 2 interventions - of which Dual mobility implant is the first listed.
NCT04092634 reports a single indexed study location in California, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT04092634 about?
NCT04092634 is a clinical study titled "Dual Mobility in "High Risk" Patients". The aim of this study is to compare clinical outcomes of patients considered to be high risk for prosthetic dislocation undergoing primary total hip arthroplasty (THA) with the use of a dual mobility bearing versus a conventional, single bearing design.
What is the current status of trial NCT04092634?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 412 participants. The study started on 2017-11-01. Estimated completion is 2035-02-01.
What conditions does trial NCT04092634 study?
This clinical trial studies the following conditions: Dislocation, Hip.
What interventions are being tested in trial NCT04092634?
The interventions under investigation include: Dual mobility implant (DEVICE), Traditional, Single-bearing hip implant (DEVICE).
Who is sponsoring clinical trial NCT04092634?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04092634 being conducted?
This trial has 4 study locations across California, Illinois, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dislocation, Hip
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04092634's enrollment target sits among peer trials
412 205th of 2000 higher than 1,796 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05993689 · 412 participants · NA
Building TrUst and UNiting Teams Through DouLa partnErship - BUNDLE
- NCT06699212 · 412 participants · Phase 3
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
- NCT03592472 · 413 participants · Phase 3
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
- NCT06697197 · 413 participants · Phase 1
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI